Pay in 4 interest-free payments of $6.82 Learn more
Ships within 48 hours · Estimated delivery Sep 11 - Sep 16
"Triple-Hormone-Receptor Agonist Retatrutide for Obesity A Phase 2 Trial." New England Journal of Medicine
Type 1 DM Autoimmune destruction of pancreatic beta cells absolute insulin deficiency
The manufacturer of both, Novo Nordisk, realized the potential the drug had in treating obesity and obesity-related illnesses, but found that higher doses of liraglutide were needed to treat obesity (hence the two different names of essentially the same drug)
We can give it orally
The blend offers several advantages over synthetic growth hormone: More natural pulsatile release Lower cost Fewer side effects Legal status (for research purposes) Maintains natural feedback mechanisms However, synthetic GH produces more dramatic results at higher doses
2 Approximate pricing as of 2026
